2月26日，Mirxes发布公告宣布，其与印度Apollo集团旗下全资子公司Apollo Health and Lifestyle签署谅 解备忘录，拟携手在印度及周边国家联合开发、商业化先进癌症早筛解决方案，并计划成立估值不低于 5000万美元的合资公司。 而就在2月23日，Mirxes宣布其CADENCE-CRC结直肠癌早筛研究完成全部入组。该研究是东南亚首个 且规模最大的血液早筛注册临床试验，招募超6000名受试者，覆盖华裔、马来裔、印度裔等多元种族， 产品早期检出灵敏度超80%、特异度约90%，为亚洲人群量身定制的临床数据，让其技术与印度市场的 适配性大幅提升。 觅瑞的产品管线布局，呈现出较为清晰的梯度结构，围绕胃癌、肺癌、结直肠癌三大癌种构建起一条有 序递进的商业化路径，精准踩中了印度的市场需求： 胃癌早筛产品是当前的核心收入支柱，作为全球首款获批的胃癌早筛IVD产品，已于2025年 在中国取得注册证。2026年至2027年将进入商业化加速期，预计为公司研发投入与市场拓展 提供稳定的现金流支持； 肺癌早筛产品于2025年落地，定位为快速跟进的增量业务，填补亚洲市场在肺癌早筛领域的 空白，与胃癌产品形成 ...

Group 1 - The 2025 Guangdong Urology Academic Conference and Bladder Cancer Academic Conference successfully concluded in Shenzhen, showcasing the innovative UriFind product from Benchmark Medical [1] - The clinical research involving 1,172 samples demonstrated that the UriFind kit has a sensitivity of 89.74%, specificity of 92.46%, and accuracy of 91.47% for the auxiliary diagnosis of urothelial carcinoma [1] - UriFind shows significant advantages in detecting early, small, residual, and recurrent bladder cancer, providing strong evidence for early screening and diagnosis [1] Group 2 - Benchmark Medical, a subsidiary of Kangsheng Global Medical Testing Group, focuses on cancer early diagnosis and screening using tumor DNA methylation sequencing technology [5] - The company develops products covering over 70% of high-incidence cancers, including lung, breast, digestive system, and urinary system cancers, throughout the entire process of early screening, diagnosis, recurrence monitoring, and companion diagnosis [5] - Benchmark Medical has also created a big data and artificial intelligence platform centered on early screening, diagnosis, and treatment of lung cancer [5]